The world at last has a public health tool it has been seeking for more than a century: a reliable vaccine against malaria that can protect at least two-thirds of the children who receive it from developing the deadly disease.
In fact, in an embarrassment of riches, the world now has two. Last week, the World Health Organization gave its recommendation to a vaccine formula called R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, following preprint publication of Phase 3 results that showed 68 to 75 percent efficacy. (The study has not yet been peer-reviewed.) That comes just three months after the rollout of a